Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Renalytix AI Plc (GB:RENX)
LSE:RENX
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-3.6Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Sep 03, 2019
|% Change Since: 35.48%
|Next Earnings Date:Mar 25, 2019
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic achievements, including Medicare coverage developments, inclusion in clinical guidelines, successful fundraising, and cost reduction efforts. However, there are challenges such as a decline in revenue and testing volumes, and adoption hurdles in the VA system. The sentiment is balanced, with positive long-term strategic developments countered by short-term operational challenges.Company Guidance
During the third quarter earnings call for Renalytix (Symbol: RENX.L), management provided a detailed overview of their financial and strategic progress. The company reported a revenue of $535,000 for Q3 2024, with 806 tests processed, 82% of which were billable. This reflects a decline from the previous year, attributed to the conclusion of a $6 million contract with Mount Sinai. Operating expenses were significantly reduced by 40% year-over-year to $6.5 million, following strategic reorganization efforts, including a 50% reduction in headcount. The net loss also decreased by 36% to $7.7 million. The launch of the FDA-authorized KidneyIntelX.dkd product and increased insurance reimbursement were highlighted as key developments. The company emphasized their strategic focus on sales growth with a 33% increase in direct-to-physician test orders quarter-over-quarter, while anticipating further growth with the expected finalization of Medicare coverage and inclusion in international clinical guidelines. Additionally, Renalytix raised $13.5 million in aggregate gross proceeds from recent financings and reported $4.7 million in cash as of March 31, excluding additional financing proceeds. The ongoing strategic review, including potential acquisition interest, was also discussed, though specifics were limited due to regulatory constraints.Positive Medicare Coverage Developments
Medicare contractor National Government Services issued a draft local coverage determination for KidneyIntelX, with expectations for a final coverage determination in the near term.
Inclusion in International Clinical Guidelines
KidneyIntelX was included in the KDIGO international clinical guidelines for chronic kidney disease, marking a significant milestone for broader adoption.
Successful Fundraising
Completed common stock equity financing rounds in March and April, raising net proceeds of approximately $13.5 million, extending the financial runway.
FDA-Authorized Product Launch
Launched the FDA-authorized KidneyIntelX.dkd product version, with commercial test orders now being received.
Cost Reduction Achievements
Year-over-year headcount reduction of 50% and overall operating expenses reduced by approximately 40%, aiming for further expense reductions.
Direct-to-Physician Sales Growth
Achieved a 33% increase in direct-to-primary-care test order rates quarter-over-quarter, indicating early growth trends.
Strategic Acquisition Interest
Received interest from multiple potential acquirers, with a competitive sale process anticipated.
---
GB:RENX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:RENX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 20, 2024 | 7.75p | 7.75p | 0.00% |
| Oct 01, 2024 | 8.00p | 8.50p | +6.25% |
| May 15, 2024 | 24.50p | 23.50p | -4.08% |
| Feb 15, 2024 | 45.50p | 32.00p | -29.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Renalytix AI Plc (GB:RENX) report earnings?
Renalytix AI Plc (GB:RENX) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Renalytix AI Plc (GB:RENX) earnings time?
Renalytix AI Plc (GB:RENX) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Renalytix AI Plc stock?
The P/E ratio of Renalytix AI is N/A.
What is GB:RENX EPS forecast?
Currently, no data Available
---